ES3031576T3 - Jak1 selective kinase inhibitor - Google Patents
Jak1 selective kinase inhibitorInfo
- Publication number
- ES3031576T3 ES3031576T3 ES20790639T ES20790639T ES3031576T3 ES 3031576 T3 ES3031576 T3 ES 3031576T3 ES 20790639 T ES20790639 T ES 20790639T ES 20790639 T ES20790639 T ES 20790639T ES 3031576 T3 ES3031576 T3 ES 3031576T3
- Authority
- ES
- Spain
- Prior art keywords
- equiv
- mmol
- amino
- methoxy
- indol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2019083376 | 2019-04-19 | ||
| PCT/CN2020/085338 WO2020211839A1 (en) | 2019-04-19 | 2020-04-17 | Jak1 selective kinase inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES3031576T3 true ES3031576T3 (en) | 2025-07-09 |
Family
ID=72837031
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES20790639T Active ES3031576T3 (en) | 2019-04-19 | 2020-04-17 | Jak1 selective kinase inhibitor |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20220220096A1 (enExample) |
| EP (1) | EP3956322B1 (enExample) |
| JP (1) | JP7555959B2 (enExample) |
| KR (1) | KR20220003537A (enExample) |
| CN (1) | CN113710664B (enExample) |
| AR (1) | AR118729A1 (enExample) |
| AU (1) | AU2020258619B2 (enExample) |
| BR (1) | BR112021020964A2 (enExample) |
| CA (1) | CA3134174A1 (enExample) |
| DK (1) | DK3956322T3 (enExample) |
| ES (1) | ES3031576T3 (enExample) |
| MX (1) | MX2021012749A (enExample) |
| PT (1) | PT3956322T (enExample) |
| TW (1) | TW202104215A (enExample) |
| WO (1) | WO2020211839A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7613778B2 (ja) * | 2020-11-26 | 2025-01-15 | 科輝智薬（深▲セン▼）新薬研究中心有限公司 | アミド化合物、医薬組成物およびその使用 |
| CN114380806B (zh) * | 2022-03-24 | 2022-06-10 | 中国药科大学 | 2-氨基-4-吲哚基嘧啶类化合物及其制备方法与应用 |
| US12240836B2 (en) * | 2022-07-05 | 2025-03-04 | Dong-A St Co., Ltd. | Compounds as GCN2 inhibitors, pharmaceutical compositions and uses thereof |
| EP4554931A1 (en) * | 2022-07-12 | 2025-05-21 | Adama Makhteshim Ltd. | Process for preparing substituted benzamides |
| CN115260128B (zh) * | 2022-09-21 | 2022-12-09 | 苏州凯瑞医药科技有限公司 | 一种新型jak抑制剂关键中间体的制备方法 |
| GB202403369D0 (en) | 2024-03-08 | 2024-04-24 | Astrazeneca Ab | Process and intermediates for the production of a jak1 inhibitor |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9198900B2 (en) * | 2011-11-10 | 2015-12-01 | Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center | Treatment of peritoneal injury using JAK inhibitors |
| JP6767491B2 (ja) * | 2015-09-25 | 2020-10-14 | ディザル（ジァンスー）ファーマシューティカル・カンパニー・リミテッド | Ｊａｋを阻害するための化合物及び方法 |
| HRP20230069T1 (hr) * | 2017-01-17 | 2023-03-17 | Astrazeneca Ab | Selektivni inhibitori jak1 |
| WO2020057669A1 (zh) * | 2018-09-21 | 2020-03-26 | 上海轶诺药业有限公司 | 一类具有激酶抑制活性的芳香杂环类化合物 |
-
2020
- 2020-04-17 TW TW109112994A patent/TW202104215A/zh unknown
- 2020-04-17 AR ARP200101101A patent/AR118729A1/es unknown
- 2020-04-17 JP JP2021561927A patent/JP7555959B2/ja active Active
- 2020-04-17 ES ES20790639T patent/ES3031576T3/es active Active
- 2020-04-17 CA CA3134174A patent/CA3134174A1/en active Pending
- 2020-04-17 PT PT207906397T patent/PT3956322T/pt unknown
- 2020-04-17 CN CN202080029899.3A patent/CN113710664B/zh active Active
- 2020-04-17 AU AU2020258619A patent/AU2020258619B2/en active Active
- 2020-04-17 KR KR1020217036576A patent/KR20220003537A/ko not_active Ceased
- 2020-04-17 EP EP20790639.7A patent/EP3956322B1/en active Active
- 2020-04-17 MX MX2021012749A patent/MX2021012749A/es unknown
- 2020-04-17 US US17/604,442 patent/US20220220096A1/en active Pending
- 2020-04-17 DK DK20790639.7T patent/DK3956322T3/da active
- 2020-04-17 BR BR112021020964A patent/BR112021020964A2/pt unknown
- 2020-04-17 WO PCT/CN2020/085338 patent/WO2020211839A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| EP3956322A1 (en) | 2022-02-23 |
| US20220220096A1 (en) | 2022-07-14 |
| PT3956322T (pt) | 2025-06-04 |
| EP3956322B1 (en) | 2025-05-14 |
| KR20220003537A (ko) | 2022-01-10 |
| WO2020211839A1 (en) | 2020-10-22 |
| BR112021020964A2 (pt) | 2021-12-14 |
| JP2022529061A (ja) | 2022-06-16 |
| CA3134174A1 (en) | 2020-10-22 |
| CN113710664A (zh) | 2021-11-26 |
| AR118729A1 (es) | 2021-10-27 |
| TW202104215A (zh) | 2021-02-01 |
| DK3956322T3 (da) | 2025-06-16 |
| JP7555959B2 (ja) | 2024-09-25 |
| AU2020258619B2 (en) | 2025-10-23 |
| MX2021012749A (es) | 2021-11-18 |
| CN113710664B (zh) | 2024-01-26 |
| EP3956322A4 (en) | 2023-05-03 |
| AU2020258619A1 (en) | 2021-09-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES3031576T3 (en) | Jak1 selective kinase inhibitor | |
| US10556908B2 (en) | Substituted imidazo[1,2-a]pyrazines as LSD1 inhibitors | |
| US10640503B2 (en) | Imidazopyridines and imidazopyrazines as LSD1 inhibitors | |
| US11053215B2 (en) | Heterocyclic compounds useful as Pim kinase inhibitors | |
| ES2873001T3 (es) | Heterociclaminas como inhibidores de PI3K | |
| ES2876933T3 (es) | Indazoles sustituidos con oxazol como inhibidores de PI3-cinasas | |
| US11229623B2 (en) | TRPV4 antagonists | |
| ES2737696T3 (es) | Pirazolopiridinas y pirazolopirimidinas | |
| US9676750B2 (en) | Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors | |
| US11078216B2 (en) | Bisaryl amides as NRF2 activators | |
| US10590077B2 (en) | TRPV4 antagonists | |
| US20160289238A1 (en) | Heterocyclic compounds as lsd1 inhibitors | |
| ES2541530T3 (es) | Derivados piridinil- y piperazinil-metiloxi-arílicos útiles como inhibidores de tirosina quinasa de bazo (SYK) | |
| RU2818002C2 (ru) | Селективный ингибитор киназы JAK1 | |
| HK40055987A (en) | Jak1 selective kinase inhibitor | |
| US11230547B2 (en) | Purine inhibitors of human phosphatidylinositol 3-kinase delta | |
| HK40055987B (zh) | Jak1选择性激酶抑制剂 |